Project Grant R43AI186577
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $301K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), under the CFDA 93.855 Allergy and Infectious Diseases Research program, awarded a $300,000 Project Grant to Life Pharms Inc. on September 19, 2025. The grant supports the development of a novel antifungal drug, LP10581, to address the growing public health crisis of invasive, drug-resistant fungal infections. The project aims to further research and testing of this novel compound, which has shown promising in vitro and in vivo...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $470,028 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to New York University (NYU) to conduct research on deciphering fungal pathogen-specific cell cycle mechanisms in order to fuel antifungal drug discovery. The 5-year grant, with a period of performance from August 21, 2025 to July 31, 2030, will focus on investigating two promising fungal cell cycle variations in the...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
- The Project Grant award of $170,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) is focused on the "Structure-Based Design of Antifungal Inhibitors Targeting the Glycosylphosphatidylinositol (GPI) Ethanolamine Phosphate Transferase, MCD4". The research aims to develop new antifungal agents with novel mechanisms of action to address emerging fungal pathogens and growing...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will support research to accelerate the discovery of novel antifungal peptides. The $642,775 award to the University of California, Davis will fund a multi-step, high-throughput screening platform leveraging one-bead one-compound (OBOC) combinatorial technology. The goal is to rapidly identify and optimize...
- The federal Project Grant award of $299,697 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel broad-spectrum antifungal agent targeting cell wall biosynthesis. The goal is to create a mechanistically unique inhibitor of the enzyme 1-3-D-glucan synthase (GS) that demonstrates potent and wide-ranging fungicidal activity, including against echinocandin-resistant...
- This Project Grant award of $782,178 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop new antifungal agents against sterolglycoside enzymes found in fungal pathogens. The research team at Stony Brook University is using a high-throughput screening approach to identify inhibitors of the sterolglycoside enzymes SGL1 and SGLA, which are essential for the pathogenicity of Cryptococcus neoformans and Aspergillus...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), is focused on the development of novel benzyl-piperidine antifungal agents to treat intractable Mucorales infections. The $299,946 award to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, MA, aims to chemically optimize a lead series of benzyl-piperidine compounds to improve their...
- This federal Project Grant award for $489,500 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research focused on identifying non-conserved regulatory elements in the cell wall stress response of the fungus Candida albicans and testing non-conserved protein regions to discover novel antifungal drug targets. Key objectives include characterizing a cell wall stress...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis. The key objectives are to establish an effective formulation, conduct toxicological and stability studies, and prepare an Investigational New Drug (IND) application...